ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
2022 July Bulletins
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲ အမုၢ်နံၤမုၢ်သီ- လါယူၤလံ 01, 2022
တၢ်ဃုသ့ၣ်ညါတၢ်အစၢ
တၢ်ပာ်ဖျါ 1721 - 1730 လၢ 3686 အစၢတဖၣ်အကျါ
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
P79R1-21 Notice of Admission (NOA) Claims Required for Home Care Claims Effective January 1, 2022
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲ အမုၢ်နံၤမုၢ်သီ- လါယူၤလံ 01, 2022
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
P25R1-22 Update: Modifier -52, -CO and -CQ Reimbursement Changes – Effective July 1, 2022
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲ အမုၢ်နံၤမုၢ်သီ- လါယူၤလံ 01, 2022
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
QP62-22 Commercial Pharmacy Benefit Exclusion for Propel®, Propel Mini®, Sinuva®
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲ အမုၢ်နံၤမုၢ်သီ- လါယူၤလံ 27, 2022
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
QP63-22 MHCP Pharmacy Benefit Update – New drug-related Prior Authorization (PA) with Quantity Limit (QL) Criteria: Ryplazim® (plasminogen, human-tvmh)
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲ အမုၢ်နံၤမုၢ်သီ- လါယူၤလံ 27, 2022
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
P44-22 New Medical, Medical Drug and Behavioral Health Policy Management Updates: Effective October 3, 2022
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲ အမုၢ်နံၤမုၢ်သီ- လါအီကူာ် 01, 2022
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
P45-22 Medical Policy Updates: Coupe Health and Self-Funded Benefit Plans managed by Blue Cross and Blue Shield of Alabama
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲ အမုၢ်နံၤမုၢ်သီ- လါအီကူာ် 01, 2022
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
QP61-22 Free Continuing Education for Mental Health Providers through 12/31/22
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲ အမုၢ်နံၤမုၢ်သီ- လါယူၤလံ 27, 2022
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
upcoming-policies-effective-september-5_-2022.pdf
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
QP47-22 Medical Drug Management Update – Alpha-1 Proteinase Inhibitors
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲအမုၢ်နံၤမုၢ်သီ- လါယူၤ 08, 2022